The criteria for inclusion were: 1, patients with levodopa-responsive parkinsonism in whom other symptoms like ataxia, myoclonus or spasticity were not the predominant symptoms during the evolution of the disease; 2, patients with homozygous or compound heterozygous PLA2G6 gene mutations; 3, patients in which sufficient clinical information was available. The gene discussed is PLA2G6; the disease is Parkinsonism.